Healthcare Industry News: female sexual dysfunction
News Release - March 10, 2006
BioSante Pharmaceuticals Presents Bio-E-Gel(TM) Data at The International Society for the Study of Women's Sexual Health Annual MeetingLINCOLNSHIRE, Ill.--(HSMN NewsFeed)--March 10, 2006--BioSante Pharmaceuticals, Inc. (Amex:BPA ) announced the Company presented Bio-E-Gel data in an oral podium presentation at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting today. The ISSWSH meeting is being held from March 9-11, 2006 in Lisbon, Portugal. The presentation was entitled, "Bio-E-Gel(TM), A Transdermal Estradiol Gel, Effectively Treats Postmenopausal Vasomotor Symptoms."
The presentation reported on the Bio-E-Gel Phase III trial which was a 12-week, randomized, double-blind, placebo-controlled study of 484 symptomatic menopausal women. The Phase III study tested three doses of Bio-E-Gel to determine the lowest effective dose and maximize the safety profile. The four co-primary endpoints, established by the FDA, are a significant decrease over placebo in the number and the severity of hot flashes at Week 4 and Week 12 of treatment.
Data also were presented on the ability of Bio-E-Gel to reduce the number of hot flashes by 100 percent. Depending on dose, approximately 25 to 52 percent of subjects in the Phase III trial had 100 percent reduction of hot flashes by the end of the study. These reductions were statistically significant compared to placebo (p less than 0.001 to p less than 0.0001).
Across the low, mid, and high Bio-E-Gel doses tested in the Phase III trial, there was a clear dose response in the reduction in the number and severity of hot flashes. By Week 4 of treatment, the mid and high doses of Bio-E-Gel showed highly significant decreases in the number and severity of hot flashes versus placebo (p less than 0.0001), and this significant response was maintained from Week 4 to Week 12 of treatment (p less than 0.0001). Beginning at Week 5, the lowest dose of Bio-E-Gel showed a highly significant decrease in the number (p less than 0.001) and severity (p less than 0.01) of hot flashes versus placebo, therefore suggesting identification of the lowest effective dose. This significant response for both number and severity of hot flashes was maintained through Week 12 (p less than 0.0001). Importantly, over 80 percent of women who used Bio-E-Gel reported "moderate" or "great" results with Bio-E-Gel (p less than 0.0001). The company in its NDA, submitted to the FDA in February, is seeking approval for all three doses.
There were no significant differences in the safety profile of any dose of Bio-E-Gel compared to placebo other than for predictable estrogen effects such as breast tenderness.
"Bio-E-Gel Phase III trial results indicate the lowest effective dose of Bio-E-Gel thereby establishing the safest dose of Bio-E-Gel for women to reduce hot flashes. We believe the low dose of Bio-E-Gel shown to be safe and effective in this trial could also be the lowest dose of estrogen available on the market to treat hot flashes, if and when approved, and will be an attractive alternative to currently marketed estrogen therapies," said Stephen M. Simes, president and CEO of BioSante. "We believe Bio-E-Gel if and when approved by the FDA will be well positioned to compete in the U.S. estrogen therapy market, currently estimated to total approximately $1.3 billion in annual sales."
Bio-E-Gel is a gel formulation of estradiol (the same estrogen made by women) designed to be quickly absorbed through the skin after topical application on the arm and shoulder delivering estradiol to the bloodstream evenly over time at minimal dosage and in a non-invasive, painless manner.
Estrogen products today are approved for the treatment of menopausal symptoms, including hot flashes. Estrogen products are not approved for and should not be used for the treatment or prevention of heart disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of stroke and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 6.8 years of treatment with oral conjugated equine estrogens (CEE 0.625 mg) alone per day, relative to placebo. The WHI study reported increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated equine estrogens (CEE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) per day.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (transdermal estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma Inc. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at www.biosantepharma.com.
For additional information about the ISSWSH Conference, visit www.isswsh.org.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Examples of forward-looking statements in this release include the statement regarding Bio-E-Gel becoming an attractive alternative to currently marketed estrogen therapies and BioSante's belief that Bio-E-Gel will be well positioned to compete in the U.S. estrogen therapy market. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 22 to 34 of BioSante's most recent Form 10-Q, which discussion also is incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Source: BioSante Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.